Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

Main Article Content

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Joseph Merola
Brigham and Women?s Hospital and Harvard Medical School, Boston, MA, USA

Jonathan Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Rebecca Zachariae
LEO Pharma A/S, Ballerup, Denmark

Rebecca Olsen
LEO Pharma A/S, Ballerup, Denmark

Andreas Wollenberg
Klinikum der Universit?t M?nchen, Klinik und Poliklinik f?r Dermatologie und Allergologie, Munich, Germany

Keywords

Atopic Dermatitis, Biologic, Tralokinumab, IL-13, Safety

Abstract

Abstract not available.

References

1. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

2. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

3. Eckert L et al. J Am Acad Dermatol 2017; 77: 274–279.e273.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

6. Bieber T. Allergy 2020; 75: 54–62.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

8. Popovic B et al. J Mol Biol 2017; 429: 208–219.

9. Wollenberg A et al. J Allergy Clin Immunol 2019; 143: 135–141.

10. Augustin M et al. J Eur Acad Dermatol Venereol 2020; 34: 142–152.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.11

Article Details

How to Cite
Simpson, E., Merola, J., Silverberg, J., Zachariae, R., Olsen, R., & Wollenberg, A. (2021). Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. SKIN The Journal of Cutaneous Medicine, 5(1), s11. https://doi.org/10.25251/skin.5.supp.11
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>